After last year’s recall of valsartan tablets, the FDA has prioritized the approval of a new generic form of the angiotensin II receptor blocker to address the drug shortage.
The FDA issued an alert regarding the safety of tofacitinib following the results of a clinical trial that showed increased risk of pulmonary embolism.
The FDA has called for the addition of a Boxed Warning alerting clinicians and patients of an increased risk of cardiovascular death with the use of a drug used for the treatment of gout.
The FDA has called for the addition of a Boxed Warning alerting clinicians and patients of an increased risk of cardiovascular death with the use of a drug used for the treatment of gout.
The FDA has issued new proposed regulations for over-the-counter sunscreens marketed in the United States updating regulatory requirements to ensure consumers have access to safe and effective sun...
The FDA Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee jointly voted on the benefit-risk profile of esketamine nasal spray for the treatment of adults...
The FDA has approved the first therapy specifically indicated (in combination with plasma exchange and immunosuppressive therapy) for the treatment of adults with acquired thrombotic thrombocytopenic...
The FDA has approved the first generic of a common treatment option for asthma in patients and for maintenance treatment of airflow obstruction and reduction of exacerbations in patients with chronic...
An advisory panel to the FDA has recommended the approval of a new treatment option for use in postmenopausal women with osteoporosis and high fracture risk.
